Literature DB >> 20452699

Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22.

Ling Yang1, Yixuan Zhang, Lingdi Wang, Fengjuan Fan, Lu Zhu, Zhigang Li, Xiangbo Ruan, Heng Huang, Zhenzhen Wang, Zhihua Huang, Yuliang Huang, Xiaoqiang Yan, Yan Chen.   

Abstract

BACKGROUND & AIMS: Interleukin-22 (IL-22) is a Th17-related cytokine within the IL-10 family and plays an important role in host defense and inflammatory responses in orchestration with other Th17 cytokines. IL-22 exerts its functions in non-immune cells as its functional receptor IL-22R1 is restricted in peripheral tissues but not in immune cells. It was recently found that IL-22 serves as a protective molecule to counteract the destructive nature of the T cell-mediated immune response to liver damage. However, it is currently unknown whether IL-22 has an effect on lipid metabolism in the liver.
METHODS: In this study, we demonstrate that IL-22 alleviates hepatic steatosis induced by high fat diet (HFD).
RESULTS: Administration of recombinant murine IL-22 (rmIL-22) was able to stimulate STAT3 phosphorylation in HepG2 cells and mouse liver. The activation of STAT3 by rmIL-22 was reduced by the over-expression of a dominant negative IL-22R1. Within hours after rmIL-22 treatment, the expression of lipogenesis-related genes including critical transcription factors and enzymes for lipid synthesis in the liver was significantly down-regulated. The levels of triglyceride and cholesterol in the liver were significantly reduced by long-term treatment of rmIL-22 in C57BL/6 and ob/ob mice fed with HFD. The HFD-induced increases of ALT and AST in ob/ob mice were ameliorated by rmIL-22 treatment. In addition, the expression of fatty acid synthase and TNF-alpha in the liver was decreased by long-term rmIL-22 administration.
CONCLUSIONS: Collectively, these data indicate that IL-22, in addition to its known functions in host defense and inflammation, has a protective role in HFD-induced hepatic steatosis via its regulation on lipid metabolism in the liver. Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452699     DOI: 10.1016/j.jhep.2010.03.004

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  68 in total

1.  Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress.

Authors:  Sumaira Z Hasnain; Danielle J Borg; Brooke E Harcourt; Hui Tong; Yonghua H Sheng; Choa Ping Ng; Indrajit Das; Ran Wang; Alice C-H Chen; Thomas Loudovaris; Thomas W Kay; Helen E Thomas; Jonathan P Whitehead; Josephine M Forbes; Johannes B Prins; Michael A McGuckin
Journal:  Nat Med       Date:  2014-11-02       Impact factor: 53.440

2.  Interleukin-22: implications for liver ischemia-reperfusion injury.

Authors:  Paul J Chestovich; Yoichiro Uchida; William Chang; Mark Ajalat; Charles Lassman; Robert Sabat; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Transplantation       Date:  2012-03-15       Impact factor: 4.939

3.  Selection of reference genes for qRT-PCR in high fat diet-induced hepatic steatosis mice model.

Authors:  Lingyan Xu; Xinran Ma; Bin Cui; Xiaoying Li; Guang Ning; Shu Wang
Journal:  Mol Biotechnol       Date:  2011-07       Impact factor: 2.695

4.  Interleukin-22 ameliorates liver fibrogenesis by attenuating hepatic stellate cell activation and downregulating the levels of inflammatory cytokines.

Authors:  Dong-Hong Lu; Xiao-Yun Guo; Shan-Yu Qin; Wei Luo; Xiao-Li Huang; Mei Chen; Jia-Xu Wang; Shi-Jia Ma; Xian-Wen Yang; Hai-Xing Jiang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 5.  Mechanisms of interleukin-22's beneficial effects in acute pancreatitis.

Authors:  Chongmin Huan; Daniel Kim; Peiqi Ou; Antonio Alfonso; Albert Stanek
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

6.  Interleukin-22 ameliorates acute severe pancreatitis-associated lung injury in mice.

Authors:  Ying-Ying Qiao; Xiao-Qin Liu; Chang-Qin Xu; Zheng Zhang; Hong-Wei Xu
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 7.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

8.  An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis.

Authors:  Juan P Arab; Tejasav S Sehrawat; Douglas A Simonetto; Vikas K Verma; Dechun Feng; Tom Tang; Kevin Dreyer; Xiaoqiang Yan; William L Daley; Arun Sanyal; Naga Chalasani; Svetlana Radaeva; Liu Yang; Hugo Vargas; Mauricio Ibacache; Bin Gao; Gregory J Gores; Harmeet Malhi; Patrick S Kamath; Vijay H Shah
Journal:  Hepatology       Date:  2020-04-27       Impact factor: 17.425

Review 9.  IL-22 in tissue-protective therapy.

Authors:  Heiko Mühl; Patrick Scheiermann; Malte Bachmann; Lorena Härdle; Anika Heinrichs; Josef Pfeilschifter
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

10.  Melatonin attenuates acute pancreatitis-associated lung injury in rats by modulating interleukin 22.

Authors:  Jia-Ping Huai; Xue-Cheng Sun; Meng-Jun Chen; Yin Jin; Xiao-Hua Ye; Jian-Sheng Wu; Zhi-Ming Huang
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.